OTC · MRVT
Miravant Medical Technologies Inc.
Healthcare · Drug Manufacturers - Specialty & Generic
$0.00
Up+$0.00 (+29900.00%)
Updated Aug 17, 2026, 10:45 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 113.57K
- P/E ratio
- -0.01
- Dividend yield
- 0.00%
- 52-week range
- — – —
- Volume
- 100
- Avg. volume
- 45.05
Price performance
MRVT price history
1M range · 0 trading sessions · Daily adjusted prices
MRVT does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
Latest MRVT news
The latest Smart Investors Daily articles mentioning MRVT.
Stock researchCompany · Overview
MRVT research
Overview
Company profile and research snapshot.
Company profile
Miravant Medical Technologies Inc. operates as a pharmaceutical research and development company. The company develops PhotoPoint, a photodynamic therapy that responds to light destroying cancerous cells; and manufactures light producing and light delivery devices. Its products include PHOTREX for the treatment of wet age-related macular degeneration or AMD; MV9411, a photoreactive drug for the treatment of plaque psoriasis; MV0633 for the treatment of atherosclerosis, atherosclerotic vulnerable plaque, and restenosis; MV2101 for the treatment of vascular access graft disease in hemodialysis patients; and MV6401 for the treatment of solid tumors. Miravant Medical Technologies Inc. was formerly known as PDT, Inc. and changed its name to Miravant Medical Technologies Inc. in September 1997. The company was founded in 1989 and is headquartered in Santa Barbara, California.
Analyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
